Cargando…

Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial

BACKGROUND: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Honghu, Wang, Yan, Huang, Yilan, Xiong, Di, Shen, Jie, Siqueiros, Lisa, Bala, Veenu, Savage, George M., Guerrero, Mario, Corado, Katya, Rosen, Marc I., Fletcher, Courtney V., Daar, Eric S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782816/
https://www.ncbi.nlm.nih.gov/pubmed/36372731
http://dx.doi.org/10.1016/j.ebiom.2022.104330
_version_ 1784857428434616320
author Liu, Honghu
Wang, Yan
Huang, Yilan
Xiong, Di
Shen, Jie
Siqueiros, Lisa
Bala, Veenu
Savage, George M.
Guerrero, Mario
Corado, Katya
Rosen, Marc I.
Fletcher, Courtney V.
Daar, Eric S.
author_facet Liu, Honghu
Wang, Yan
Huang, Yilan
Xiong, Di
Shen, Jie
Siqueiros, Lisa
Bala, Veenu
Savage, George M.
Guerrero, Mario
Corado, Katya
Rosen, Marc I.
Fletcher, Courtney V.
Daar, Eric S.
author_sort Liu, Honghu
collection PubMed
description BACKGROUND: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text reminders. METHODS: Participants were recruited from HIV clinics in Los Angeles and were randomised 1:1 to IS or usual care (UC) group. Adherence to ARVs (primary outcome) was measured by IS system (IS group only), plasma ARV concentration, and self-report. IS-measured adherence was clustered by group-based trajectory model and was validated by ARV concentration summarized by integrated pharmacokinetic adherence measure (IPAM) score. HIV RNA viral load (VL) was compared between IS and UC group. FINDINGS: A total of 112 (IS = 54, UC = 58) participants who completed baseline with at least one follow-up data collection were included in analyses. Overall satisfaction rate for the IS system was >90%. The IPAM score was higher (0.018, 95% CI: −0.098–0.134, p = 0.75) and VL decayed faster (−0.020, 95% CI: −0.042–0.002, p = 0.08) in the IS group compared with the UC group. The ingestible sensor system was well tolerated by study participants. INTERPRETATION: The IS system was well accepted by participants and its use was associated with improved adherence and lower HIV RNA VL. The findings provide a potentially effective strategy for improving adherence. FUNDING: This work was supported by grant R01-MH110056 from the National Institute of Mental Health (NIMH)/10.13039/100000002National Institutes of Health (NIH). Y. Wang was in part supported by the NIMH/NIH award T32MH080634. E. Daar was in part supported by the National Center for Advancing Translational Sciences through 10.13039/100007185UCLA10.13039/100006975CTSI Grant UL1TR001881. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
format Online
Article
Text
id pubmed-9782816
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97828162022-12-24 Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial Liu, Honghu Wang, Yan Huang, Yilan Xiong, Di Shen, Jie Siqueiros, Lisa Bala, Veenu Savage, George M. Guerrero, Mario Corado, Katya Rosen, Marc I. Fletcher, Courtney V. Daar, Eric S. eBioMedicine Articles BACKGROUND: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) has the capacity to monitor adherence in real-time using a sensor patch, a mobile device, and supporting software. We evaluated the acceptability, effectiveness, and sustainability of the IS system with real-time text reminders. METHODS: Participants were recruited from HIV clinics in Los Angeles and were randomised 1:1 to IS or usual care (UC) group. Adherence to ARVs (primary outcome) was measured by IS system (IS group only), plasma ARV concentration, and self-report. IS-measured adherence was clustered by group-based trajectory model and was validated by ARV concentration summarized by integrated pharmacokinetic adherence measure (IPAM) score. HIV RNA viral load (VL) was compared between IS and UC group. FINDINGS: A total of 112 (IS = 54, UC = 58) participants who completed baseline with at least one follow-up data collection were included in analyses. Overall satisfaction rate for the IS system was >90%. The IPAM score was higher (0.018, 95% CI: −0.098–0.134, p = 0.75) and VL decayed faster (−0.020, 95% CI: −0.042–0.002, p = 0.08) in the IS group compared with the UC group. The ingestible sensor system was well tolerated by study participants. INTERPRETATION: The IS system was well accepted by participants and its use was associated with improved adherence and lower HIV RNA VL. The findings provide a potentially effective strategy for improving adherence. FUNDING: This work was supported by grant R01-MH110056 from the National Institute of Mental Health (NIMH)/10.13039/100000002National Institutes of Health (NIH). Y. Wang was in part supported by the NIMH/NIH award T32MH080634. E. Daar was in part supported by the National Center for Advancing Translational Sciences through 10.13039/100007185UCLA10.13039/100006975CTSI Grant UL1TR001881. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Elsevier 2022-11-10 /pmc/articles/PMC9782816/ /pubmed/36372731 http://dx.doi.org/10.1016/j.ebiom.2022.104330 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Liu, Honghu
Wang, Yan
Huang, Yilan
Xiong, Di
Shen, Jie
Siqueiros, Lisa
Bala, Veenu
Savage, George M.
Guerrero, Mario
Corado, Katya
Rosen, Marc I.
Fletcher, Courtney V.
Daar, Eric S.
Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
title Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
title_full Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
title_fullStr Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
title_full_unstemmed Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
title_short Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial
title_sort ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: an open-label, usual care-controlled, randomised trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782816/
https://www.ncbi.nlm.nih.gov/pubmed/36372731
http://dx.doi.org/10.1016/j.ebiom.2022.104330
work_keys_str_mv AT liuhonghu ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT wangyan ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT huangyilan ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT xiongdi ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT shenjie ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT siqueiroslisa ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT balaveenu ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT savagegeorgem ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT guerreromario ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT coradokatya ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT rosenmarci ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT fletchercourtneyv ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial
AT daarerics ingestiblesensorsystemformeasuringmonitoringandenhancingadherencetoantiretroviraltherapyanopenlabelusualcarecontrolledrandomisedtrial